Ariceum Therapeutics is a privately held radiopharmaceutical firm in the clinical stage that specializes in the detection and targeted treatment of aggressive malignancies, such as neuroendocrine and other hard-to-treat cancers.177Lu-satoreotide tetraxetan (Satoreotide), the company's primary targeted systemic radiopharmaceutical therapy, isan antagonist of the somatostatin type 2 receptor (SSTR2), which is overexpressed in many neuroendocrine tumors. For the simultaneous diagnosis and targeted radionuclide treatment of neuroendocrine malignancies, some aggressive tumors, and childhood cancer, which currently offers few treatment choices and a poor prognosis, we are developing satoreotide as a "theranostic" pair.

Therapeutics

Health Care

Biotechnology

Ariceum Therapeutics

Manfred Ruediger

Greg Mullen, PhD, FRSC

Serge SAGODIRA

Marion H.

Manuel Sturzbecher-Hoehne

Germo Gericke

Dennis MEWIS

Anika Jäkel

Clinical Development Team

Leadership Team

Teams at Ariceum Therapeutics

Clinical Development Team

Leadership Team